2026年11月4日星期三
M
Küresel Panorama
Küresel haberler
Nintendo's Mario creator Miyamoto sees 'things we can do' even in AI era— 日经 Nikkei AsiaDebt costs curb growth for developing nations, Rockefeller official says— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei AsiaThe best is yet to come: Asia's chance to reimagine AI— 日经 Nikkei AsiaUS tech giants' hidden AI debt swells 90% to $3.2tn in 6 months— 日经 Nikkei AsiaNintendo's Mario creator Miyamoto sees 'things we can do' even in AI era— 日经 Nikkei AsiaDebt costs curb growth for developing nations, Rockefeller official says— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei AsiaThe best is yet to come: Asia's chance to reimagine AI— 日经 Nikkei AsiaUS tech giants' hidden AI debt swells 90% to $3.2tn in 6 months— 日经 Nikkei Asia

[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial

Kaynak 柳叶刀 Lancet11 gün önce
İçerik özeti

Mitapivat, an oral pyruvate kinase activator, with a novel mechanism that ameliorates haemolytic anaemia, has the potential to be an effective and convenient d…

Bu site yalnızca başlık ve özet dizini sunar; tam içerik ve telif hakkı asıl yayıncıya aittir, lütfen okumak için orijinal bağlantıya tıklayın.

Orijinal metne git
Ait olduğu kanal
Sağlık
Ait olduğu bölge
Birleşik Krallık
Orijinal dil
English
Kayıt numarası
health-94d31632

Comments 0 comments

No comments yet. Be the first.

[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial · Küresel Panorama